Bank Of New York Mellon Corp Ventyx Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $2.67 Million - $4.02 Million	110,387 New	110,387 $3.62 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $381,133 - $1.17 Million	30,153 Added 59.96%	80,445 $2.81 Million
Q2 2022 Aug 15, 2022	BUY	$11.95 - $18.75 $311,297 - $488,437	26,050 Added 107.46%	50,292 $615,000
Q1 2022 May 11, 2022	BUY	$10.0 - $19.98 $66,880 - $133,626	6,688 Added 38.1%	24,242 $329,000
Q4 2021 Feb 11, 2022	BUY	$14.2 - $23.07 $249,266 - $404,970	17,554 New	17,554 $349,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.